Japan To Support Trials Of 50 Drugs For Critical Diseases
This article was originally published in PharmAsia News
Japan's health ministry says it will provide more than $791 million in support for clinical trials by the nation's drug makers to test 50 selected treatments for incurable and critical ailments. The Ministry of Health, Labor and Welfare said it invites various institutions, organizations and patient groups to recommend the treatments to be covered over a three-year period. The ministry said it also would expedite approvals for such drugs by cutting in half the process for reviewing them, now a one-year process. The drugs to be covered would be limited to those already approved in France, Germany, the United Kingdom and the United States. (Click here for more
You may also be interested in...
While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic eﬀectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir & ivermectin.
Virtual trials could be the answer to limitations placed on innovation by the coronavirus pandemic and help companies formulate new health claims relevant to a new generation of consumers, argued IQVIA Consumer Health during a recent webinar.
Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.